Given the potent pro-apoptotic effects of c-MET inhibitors, we evaluated the combination of capmatinib and ABT-199 (also known as venetoclax), a highly selective and effective BCL-2 inhibitor that has shown remarkable efficacy in treating CLL (Lasica and Anderson, 2021). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.